Apraklonidin se administrira u koncentraciji od 1% za sprečavanje i tretman povišenog posthirurškog intraokularnog pritiska i 0.5% za kratkotrajnu adjunktivnu terapiju kod pacijenata na maksimalno tolerisanoj medicinskoj terapiji kojima je neohodna dodatna redirekcija intraokularnog pritiska. Jedna kap se obično dodaje jedan sat pre laserske operacije oka i još jedna kap nakon završetka procedure.
↑Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
Chen P, Chen J, Lu D, Chen Y, Hsiao C (2006). „Comparing efficacies of 0.5% apraclonidine with 4% cocaine in the diagnosis of horner syndrome in pediatric patients”. J Ocul Pharmacol Ther22 (3): 182–7. DOI:10.1089/jop.2006.22.182. PMID16808679.
Aslanides l, Tsiklis N, Ozkilic E, Coskunseven E, Pallikaris l, Jankov M (2006). „The effect of topical apraclonidine on subconjunctival hemorrhage and flap adherence in LASIK patients”. J Refract Surg22 (6): 585–8. PMID16805122.
Garibaldi D, Hindman H, Grant M, Iliff N, Merbs S (2006). „Effect of 0.5% apraclonidine on ptosis in Horner syndrome”. Ophthal Plast Reconstr Surg22 (1): 53–5. DOI:10.1097/01.iop.0000196322.05586.6a. PMID16418668.
Onal S, Gozum N, Gucukoglu A (2005). „Effect of apraclonidine versus dorzolamide on intraocular pressure after phacoemulsification”. Ophthalmic Surg Lasers Imaging36 (6): 457–62. PMID16355950.